Heberprot-p

By María Josefina Arce

A flagship product of Cuban biotechnology, HEBERPROT-P, continues to expand its presence in the world and to benefit more patients with diabetic foot ulcers, a global health problem.

The internationally recognised medicine will now reach the United Arab Emirates, thanks to recent agreements between Cuba and the United Arab Emirates for the commercialisation of Cuban biotechnology products.

This is good news for the citizens of that Arab nation, given the high efficacy of HEBERPROT-P, created by the Centre for Genetic Engineering and Biotechnology of the Greater Antilles.

Without a doubt, it is now a drug known in much of the world. It is registered in 26 nations, including Russia, Argentina, Vietnam and Mongolia, and has improved the quality of life of many citizens with diabetes who develop ulcers.

According to studies, 85% of lower limb amputations in people with diabetes are triggered by ulcers.

This medicine has brought hope to patients with this condition. The only one of its kind in the world, it reduces the healing time of these lesions, thereby reducing the risk of amputation.

In the Caribbean nation, after exhaustive clinical trials that demonstrated its efficacy, it was included in the basic list of medicines in 2013, and since then its widespread use has become the norm.

In addition, it was recently used for the first time on a Cuban child who had suffered a traffic accident. Its successful application prevented amputation and the subsequent use of a prosthesis.HEBERPROT-P will be one of the products to be marketed in the United Arab Emirates and once again demonstrates the confidence in Cuban biotechnology, whose progress is internationally renowned.

Our scientific community, even in the midst of the limitations imposed by the US blockade, has created drugs that currently make a difference and represent hope for many people in the world suffering from various ailments.